Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III safety study of add-on QAW039 in inadequately controlled GINA 3/4/5 asthma
CTR20181095Phase 3Suspended
- Sponsor
- Novartis
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fevipiprant in asthma, sponsored by Novartis. Started Sep 2018; status: suspended.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20181095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181095.